
Sepsis, the leading cause of acute kidney injury (AKI), is associated with high morbidity and mortality. Alkaline phosphatase (ALP) is an endogenous detoxifying enzyme. A recombinant human ALP compound, ilofotase alfa, showed no safety or tolerability concerns in a phase 2 trial. However, renal function improvement over 28 days was significantly more significant in the ilofotase alfa group. Moreover, a significant relative reduction in 28-day all-cause mortality of >40% was observed. A follow-up trial has been designed to confirm these findings. The results of this study will determine the potential of ilofotase alfa to reduce mortality in critically ill patients with sepsis-associated AKI.
Like
Save
Share